Roctavian Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The roctavian market research report is one of a series of new reports that provides roctavian market statistics, including roctavian industry global market size, regional shares, competitors with a roctavian market share, detailed roctavian market segments, market trends and opportunities, and any further data you may need to thrive in the roctavian industry. This roctavian market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to increasing focus on developing advanced therapies, increasing gene therapy's success rates, increasing propensity for preventive treatment, increasing the number of disease therapeutics, and growing prevalence of genetic disorders. Major trends in the forecast period include innovative treatments and therapies, technological advancements, FDA approvals, novel therapeutic products, and clinical trials and regulatory approvals.

The growing prevalence of hemophilia is expected to drive the expansion of the roctavian market in the coming years. Hemophilia is a genetic disorder that results in improper blood clotting due to a deficiency in clotting factors, and it is typically treated with replacement therapy. The rise in the prevalence of hemophilia is largely due to better diagnosis, increased awareness, and genetic testing that are identifying more cases. Roctavian treats hemophilia A through a one-time gene therapy infusion that enables the body to produce its own Factor VIII, reducing the frequency of bleeding episodes and the need for regular clotting factor treatments. For example, according to a report by the World Federation of Hemophilia in October 2022, there were 427,685 cases of bleeding disorders globally, including 257,146 cases of hemophilia. This increase in the prevalence of hemophilia is helping drive the growth of the roctavian market.

The rising healthcare investments are expected to further fuel the growth of the roctavian market. Healthcare investments involve allocating capital to sectors such as pharmaceuticals, medical devices, and digital health to foster growth and innovation. These investments are being driven by factors such as an aging population, technological advancements, and the increasing burden of chronic diseases. In the case of roctavian, healthcare investments support its research, clinical trials, regulatory approvals, manufacturing, and market access strategies to ensure the treatment becomes widely available and effective. For example, in May 2023, the Office for National Statistics in the UK reported that healthcare expenditure reached approximately $354.88 billion (£283 billion) in 2022, showing a modest increase of 0.7% from the previous year. These rising healthcare investments are helping propel the growth of the roctavian market.

A key factor driving market expansion for roctavian is securing regulatory approvals to extend its reach to more regions and patient groups, enabling broader access to this innovative gene therapy. Regulatory approvals are granted by health authorities after confirming a product's safety, efficacy, and quality. For instance, in June 2023, BioMarin Pharmaceutical Inc. received approval from the U.S. Food and Drug Administration (FDA) for Roctavian, the first and only gene therapy for adults with severe hemophilia A. This breakthrough treatment aims to enable patients to produce their own Factor VIII, which significantly reduces bleeding episodes and the need for regular infusions. The approval was based on the positive outcomes from the GENEr8-1 clinical trial, which demonstrated that the therapy effectively decreased bleeding rates. With an estimated 2,500 eligible adults in the U.S., this approval marks a major milestone in the treatment of hemophilia A, offering hope for improved patient outcomes.

The key company operating in the roctavian market is BioMarin Pharmaceutical Inc.

North America was the largest region in the roctavian market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in roctavian report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the roctavian market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Roctavian is a gene therapy developed for the treatment of hemophilia A, a genetic disorder caused by a deficiency in clotting factor VIII. The therapy introduces a functional copy of the factor VIII gene, allowing the body to naturally produce the necessary clotting factor. It offers the possibility of long-term or even permanent relief from the condition.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main clinical indications for Roctavian include severe hemophilia A, prophylactic therapy, patients without factor VIII inhibitors, and those with neutralizing antibodies to AAV5. Severe hemophilia A is a genetic disorder characterized by very low or absent levels of clotting factor VIII, which is crucial for blood clotting. Roctavian is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving a variety of end users, including hospitals, specialty clinics, homecare providers, and research institutions.

The roctavian market consists of sales of coagulation factor VIII products, immunosuppressive medications, and recombinant factor IX products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises generate from the sale of goods and services within a specific market and geography, whether through sales, grants, or donations, expressed in the specified currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.